Our findings also shed light on key signaling pathways involving CD248+ CAFs that contribute to tumor immune escape and propose a potential therapeutic strategy targeting this axis for improved NSCLC treatment outcomes. This evidence concerns the gene CD248 and non-small cell lung carcinoma.